This is a comment on the article by Fukui et al. investigating the relationship between tumor-infiltrating lymphocytes (TILs) and response to neoadjuvant endocrine therapy in estrogen receptor-positive/HER2-negative breast cancer. While their data are quite interesting, some information crucial for interpreting the results of this study is missing. Therefore, I would like the authors to provide additional data.